Epigenetic Features of FoxP3 in Children With Cow's Milk Allergy
NCT02779881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2016-05-23
Summary
Epigenetic mechanisms have been implicated in the pathogenesis of food allergy. The investigators previously demonstrated that tolerance acquisition in children with Immunoglobulin E- (IgE) mediated cow's milk allergy (CMA) is driven by epigenetic modulation of the Th1 and Th2 cytokine genes. A regulatory T cell (Treg) suppressive phenotype, characterized by stable expression of the transcription factor "Forkhead box Protein 3" (FoxP3), plays a pivotal role in food tolerance. FoxP3 mRNA expression is lower in children with atopic asthma or IgE-mediated food allergy than in healthy children. FoxP3 stable expression requires full CpG demethylation of its transcriptional regulatory regions, and, moreover, hypermethylation of the FoxP3 gene has been associated with reduced Treg function and allergy.
DNA methylation is a biologically and chemically stable epigenetic modification that locks in long-term gene expression patterns. The demethylation status of FoxP3 at a highly conserved region within the Treg-specific-demethylated-region (TSDR), a CpG-rich, located on the 2nd conserved non-coding sequence of FoxP3 (CNS2), is restricted to Tregs. Transcriptional activity of the TSDR is essentially determined by its methylation status : it is completely inactive in its methylated state, but when the TSDR is demethylated, transcription factors such as Ets-1 and Creb can bind to the TSDR. TSDR demethylated and open chromatin conformation in the Foxp3 locus leads to stable phenotype differentiated Foxp3+ Treg. FoxP3 TSDR demethylation in peripheral blood mononuclear cells (PBMCs) has been associated with reduced atopic sensitization and asthma in children. Epigenetic regulation of antigen-induced T-cell subsets may predict a state of immune tolerance in food allergy. Indeed, DNA methylation of the FoxP3 gene in Tregs decreased during oral tolerance acquisition in patients with peanut allergy undergoing oral immunotherapy. The aim of this study was to evaluate further the epigenetic regulation of FoxP3 gene in children with IgE-mediated CMA.
Conditions
- Cow's Milk Allergy
Interventions
- DIETARY_SUPPLEMENT
-
Extensively hydrolyzed casein formula plus LGG
Sponsors & Collaborators
-
Federico II University
lead OTHER
Eligibility
- Min Age
- 3 Months
- Max Age
- 18 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-31
- Primary Completion
- 2014-04-30
- Completion
- 2014-04-30
Countries
- Italy
Study Locations
More Related Trials
-
Hypoallergenicity To Substitutive Formulas In Children With Cow's Milk Allergy
NCT02144428 ·Status: UNKNOWN
-
Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)
NCT02466035 ·Status: COMPLETED ·Phase: NA
-
Cow's Milk Allergy and Functional Gastrointestinal Disorders
NCT01901380 ·Status: COMPLETED
-
Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy
NCT02379598 ·Status: COMPLETED
-
Hypoallergenicity of a New Formula in Subjects With Cow's Milk Allergy
NCT06134466 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Tolerance of a New Formula Based on Hydrolyzed Rice Proteins in Children With Cow's Milk Allergy
NCT07197814 ·Status: RECRUITING ·Phase: NA
-
Efficacy of the "Milk Ladder" Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins
NCT03466931 ·Status: UNKNOWN ·Phase: NA
-
Effect Of Lactobacillus GG on Atopic March
NCT01891916 ·Status: UNKNOWN ·Phase: NA
-
Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations
NCT03861910 ·Status: COMPLETED
-
Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy
NCT02149134 ·Status: UNKNOWN ·Phase: PHASE2
-
Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy
NCT02351531 ·Status: COMPLETED ·Phase: PHASE3
-
Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy
NCT06633289 ·Status: COMPLETED ·Phase: NA
-
Suspicion of Non IgE-mediated Cow's Milk Protein Allergy: Prevalence and Evolution
NCT04651829 ·Status: COMPLETED
-
Detection of Metabolite Biomarkers for the Early Diagnosis and Prognosis of Cow's Milk Allergy in Children
NCT04249973 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula
NCT02711163 ·Status: COMPLETED ·Phase: PHASE3
-
Early Oral Immunotherapy in Infants With Cow's Milk Protein Allergy
NCT03586388 ·Status: COMPLETED ·Phase: NA
-
Formula for Children With Cow's Milk Allergy
NCT02317952 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
NCT03557671 ·Status: COMPLETED ·Phase: NA
-
Specific Oral Tolerance Induction in Children Allergic to Cow's Milk Proteins
NCT01641731 ·Status: COMPLETED ·Phase: NA
-
Polymerized Beta-lactoglobulin Comparative Immunoreactivity
NCT01589731 ·Status: COMPLETED
-
Oral Tolerance in Cow's Milk Allergy in the Infant
NCT00298376 ·Status: UNKNOWN
-
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
NCT01998074 ·Status: COMPLETED ·Phase: NA
-
Free Amino Acid-based Formula to Treat Children Cow's Milk Protein Allergy
NCT02536482 ·Status: COMPLETED ·Phase: PHASE2
-
Growth and Plasma Amino Acids in Infants With CMPA and Treated With a Newly Innovated Amino Acid Formula
NCT01637688 ·Status: UNKNOWN
-
Hypoallergenicity of a Hydrolyzed Protein Infant Formula
NCT05731206 ·Status: SUSPENDED ·Phase: NA